https://vigeotx.com/news/vigeo-therapeutics-to-present-new-phase-1-2-vt1021-dose-escalation-and-expansion-data-at-the-society-for-immunotherapy-of-cancers-2020-annual-meeting/ 2021-02-28T19:44:26+00:00 https://vigeotx.com/news/vigeo-therapeutics-doses-first-patients-in-expansion-phase-of-its-1b-2-study-investigating-vt1021-in-patients-with-cd36-expressing-cancers/ 2021-02-28T19:44:35+00:00 https://vigeotx.com/news/vigeo-therapeutics-to-present-at-the-2019-bio-investor-forum/ 2021-02-28T19:44:41+00:00 https://vigeotx.com/news/vigeo-therapeutics-to-present-results-from-its-phase-1-study-evaluating-vt1021-in-patients-with-advanced-solid-tumors-at-the-european-society-for-medical-oncology-esmo-2019-congress/ 2021-02-28T19:44:48+00:00 https://vigeotx.com/news/vigeo-therapeutics-presents-preliminary-results-from-its-phase-1-open-label-trial-of-vt1021-in-patients-with-advanced-solid-tumors-at-asco/ 2021-02-28T19:44:52+00:00 https://vigeotx.com/news/biotech-strategy-blog-interview-with-vigeo-ceo-and-co-founder/ 2021-03-02T22:36:18+00:00 https://vigeotx.com/news/vigeos-tumor-microenvironment-platform-expands-indications-and-combo-therapy-possibilities/ 2021-03-02T22:36:57+00:00 https://vigeotx.com/news/what-immuno-oncology-research-can-tell-us-about-covid-19/ 2021-05-05T19:37:19+00:00 https://vigeotx.com/news/cancer-patients-can-not-afford-to-put-their-struggle-on-hold/ 2021-07-07T14:06:23+00:00 https://vigeotx.com/news/viewpoints-interview/ 2021-07-13T17:29:07+00:00 https://vigeotx.com/news/vigeo-therapeutics-provides-clinical-update-for-lead-asset-vt1021-and-welcomes-new-chief-executive-officer/ 2021-09-21T12:50:16+00:00 https://vigeotx.com/news/vigeo-therapeutics-to-present-new-phase-1-2-vt1021-data-from-its-pancreatic-cancer-expansion-study-at-the-society-for-immunotherapy-of-cancers-2021-annual-meeting/ 2021-10-01T15:26:11+00:00 https://vigeotx.com/news/vigeo-therapeutics-announces-new-phase-1-2-data-from-its-expansion-study-of-vt1021-at-the-society-for-immunotherapy-of-cancers-2021-annual-meeting/ 2021-11-09T13:02:07+00:00 https://vigeotx.com/news/vigeo-therapeutics-announces-new-phase-1-2-data-from-its-expansion-study-of-vt1021-at-the-society-of-neurooncologys-2021-annual-meeting/ 2021-11-16T12:00:51+00:00 https://vigeotx.com/news/vigeo-therapeutics-advances-vt1021-into-phase-2-3-registrational-study-for-glioblastoma/ 2022-07-13T15:14:09+00:00 https://vigeotx.com/news/global-coalition-for-adaptive-research-biohaven-and-vigeo-announce-commencement-of-biohavens-troriluzole-and-vigeos-vt1021-in-gbm-agile-trial/ 2022-07-13T15:30:00+00:00 https://vigeotx.com/news/groundbreaking-discovery-by-vigeo-cofounder-randolph-watnick-demonstrates-a-novel-role-of-prss2-in-creating-an-immunosuppressive-tumor-microenvironment/ 2023-01-27T21:58:00+00:00 https://vigeotx.com/news/global-coalition-for-adaptive-research-and-gbm-agile-partners-to-ring-the-nasdaq-stock-market-closing-bell-in-honor-of-national-brain-tumor-awareness-month/ 2023-05-19T12:03:58+00:00 https://vigeotx.com/news/vigeo-therapeutics-new-immune-profiling-and-biomarker-data-ph-i-ii-expansion-study-in-gbm-patients/ 2023-05-25T21:05:15+00:00 https://vigeotx.com/news/vigeo-therapeutics-will-present-new-clinical-and-immune-profiling-data-from-ph-i-ii-expansion-study-in-gbm-patients-in-asco-poster-oral-session/ 2023-06-02T10:57:13+00:00 https://vigeotx.com/news/vigeo-therapeutics-provides-clinical-update-on-vt1021-treatment-of-gbm-expansion-patient/ 2023-07-13T10:58:16+00:00 https://vigeotx.com/news/a-wonderful-feeling-hudson-man-with-aggressive-brain-tumor-defies-odds/ 2023-09-20T15:01:46+00:00 https://vigeotx.com/news/vigeo-therapeutics-to-present-at-the-2024-glioblastoma-drug-development-summit-in-boston-massachusetts/ 2024-03-26T14:39:18+00:00